TearLab (OTCMKTS:TEAR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.
This table compares TearLab and Pro-Dex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for TearLab and Pro-Dex, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
11.5% of Pro-Dex shares are owned by institutional investors. 5.2% of TearLab shares are owned by insiders. Comparatively, 41.7% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares TearLab and Pro-Dex’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TearLab||$27.12 million||0.04||-$16.10 million||N/A||N/A|
|Pro-Dex||$22.47 million||2.61||$1.62 million||N/A||N/A|
Pro-Dex has lower revenue, but higher earnings than TearLab.
Volatility & Risk
TearLab has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Pro-Dex beats TearLab on 7 of the 9 factors compared between the two stocks.
TearLab Company Profile
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
Pro-Dex Company Profile
Pro-Dex, Inc. engages in the design, development, and manufacture of rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. It specializes in medical device and services, industrial and scientific, dental and component, repairs, and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding, and torque wrenches. The company was founded on January 26, 1994 and is headquartered in Irvine, CA.
Receive News & Ratings for TearLab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab and related companies with MarketBeat.com's FREE daily email newsletter.